Effect of Benazepril Hydrochloride and Sacubitril/Valsartan in Patients with Heart Failure with Reduced Ejection Fraction Complicated with Atrial Fibrillation
Objective To explore the effect of benazepril hydrochloride and sacubitril/valsartan in patients with heart failure with reduced ejection fraction(HF-REF)complicated with atrial fibrillation.Methods A total of 196 patients with HF-REF and persistent atrial fibrillation admitted to Zhengzhou Central Hospital Affiliated to Zhengzhou University from September 2020 to September 2022 were divided into conventional group and observation group according to the random number table method,with 98 cases in each group.Both groups received basic treatment,and the conventional group was treated with benazepril hydrochloride tablets,and the observation group was given sacubitril/valsartan.The therapeutic effect,cardiac function indicators[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)],ventricular remodeling indicators[interventricular septal thickness(IVST),left ventricular posterior wall thickness(LVPWT),left ventricular myocardial mass index(LVMI)],serum high-sensitivity C-reactive protein(hs-CRP),neuroendocrine factors[N-terminal pro-brain natriuretic peptide(NT-proBNP)and brain natriuretic peptide(BNP)],myocardial fibrosis indicators[tissue inhibitor of metalloproteinase-1(TIMP-1),soluble growth stimulation expressed gene 2(sST2)]and adverse reactions were compared between the two groups.Results Compared with conventional group,the total effective rate of treatment in observation group was higher after 6 months of treatment(P＜0.05).After treatment,the LVEF in observation group was higher than that in conventional group,while the levels of hs-CRP,NT-proBNP,BNP,TIMP-1,sST2 and the LVESD,LVEDD,I VST,LVPWT and LVMI were lower compared with those in conventional group(P＜0.05).The incidence rates of adverse reactions in observation group were lower compared to conventional group(P＞0.05).Conclusion Sacubitril/valsartan can effectively promote the improvement of cardiac function,inhibit the myocardial fibrosis and ventricular remodeling,and it has low incidence rates of adverse reactions and exact safety and efficacy.
benazepril hydrochloridesacubitril/valsartanejection fractionheart failure complicated with atrial fibrillationmyocardial fibrosisventricular remodeling
万方数据
维普
